RxDoctor Payments Data

Edith Akintokunbo, MD

Family Medicine · Sugar Land, TXNPI 1902191240

Payments from drug & device makers

$2,620in general payments, 2019–2025

Across 94 payments — averaging $27.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$899
  • Medline Industries LP$451
  • Organogenesis Inc.$262
  • KCI USA, Inc.$91
  • Johnson & Johnson$90
  • AbbVie$87
  • plus $739 from 20 others

What the payments were for

  • Food & beverage$2,620100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,620 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$127,157
Medicare patients
190
Services billed
1,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin45$62,920
OzempicSemaglutide25$34,277
EliquisApixaban24$32,443
SantylCollagenase Clostridium Hist.19$17,341
ShingrixVaricella-Zoster Ge/As01b/Pf12$2,582
Mirtazapine33$1,947
Brimonidine Tartrate11$1,394
Atorvastatin Calcium114$1,044
Albuterol Sulfate HfaAlbuterol Sulfate30$963
Gabapentin38$914
Amlodipine Besylate119$626
Olmesartan Medoxomil34$579
Metoprolol Succinate36$470
Amlodipine-ValsartanAmlodipine Besylate/Valsartan11$438
Levothyroxine Sodium30$430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$21$62,92045 claims
Novo NordiskOzempic$25$34,27725 claims
Smith+NephewSantyl$899$17,34119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →